Mechanism of Action
Neurotensin Receptor Subtypes
Neurotensin signals through three receptor subtypes: NTS1, NTS2 (G-protein-coupled), and NTS3 (sortilin, a single-pass membrane receptor). NTS1 is the primary mediator of CNS effects and is widely expressed in dopaminergic and serotonergic pathways. NTS2 modulates pain transmission and has a lower affinity for neurotensin. NTS3/sortilin is involved in intracellular trafficking and neuronal survival.
Dopamine System Modulation
Neurotensin is co-released with dopamine in the mesolimbic and nigrostriatal pathways, acting as an endogenous modulator of dopamine function. NTS1 activation on dopaminergic neurons inhibits firing and reduces dopamine release, producing effects pharmacologically similar to antipsychotic drugs. This mechanism does not involve D2 receptor blockade, potentially avoiding the motor side effects of classical antipsychotics.
Thermoregulation and Pain
Central neurotensin administration produces potent hypothermia through hypothalamic NTS1 receptors, independent of opioid pathways. Neurotensin also produces analgesic effects that are naloxone-insensitive, suggesting distinct pain modulatory mechanisms from the classical opioid system. These findings support investigation as a non-opioid analgesic.
Research Summary
Schizophrenia and Psychosis
HumanCSF neurotensin levels are reduced in untreated schizophrenia and normalize with antipsychotic treatment. NTS1 agonists produce antipsychotic-like effects in animal models without D2 blockade, motivating pharmaceutical development. Several NTS1 agonist programs have advanced to early clinical assessment.
Addiction Research
AnimalNeurotensin modulates mesolimbic dopamine responses to drugs of abuse including cocaine, amphetamine, and alcohol. Central neurotensin administration reduces stimulant-induced hyperlocomotion and conditioned place preference in rodent models, suggesting potential applications in addiction treatment.
GI and Metabolic Effects
AnimalPeripheral neurotensin inhibits gastric emptying, stimulates pancreatic enzyme secretion, and promotes fat absorption in the small intestine. NT levels rise after fatty meals, contributing to satiety signaling. These GI actions have prompted research into neurotensin in obesity and metabolic syndrome.
Calculate your Neurotensin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| CNS research | 1-10 nmol/kg | Single or repeated injections | Subcutaneous or ICV (animal) |
| Satiety / metabolic research | 10-100 nmol/kg | Pre-meal | Subcutaneous (animal) |
Very short half-life limits peripheral administration. Most CNS research uses central delivery or analogs.
Interactions
Safety Profile
Peripheral neurotensin has a very short plasma half-life, limiting systemic exposure. Hypothermia and hypotension are dose-dependent central effects that could limit therapeutic use. Animal studies have not identified significant organ toxicity. Development of stable NT analogs aims to retain therapeutic effects while improving pharmacokinetic properties.
References
- [1]Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem. 1973;248(19):6854-6861.
- [2]Binder EB, et al. Neurotensin and dopamine interactions. Pharmacol Rev. 2001;53(4):453-486.
- [3]Boules M, et al. Neurotensin: role in psychiatric and neurological diseases. Prog Neurobiol. 2013;100:1-19.